



## Vaccination in Neurological Autoimmune Disorders

Guest Editors:

**Dr. Siddappa Byrareddy**

**Dr. Mary Rensel**

**Dr. Gabrielle Macaron**

Deadline for manuscript  
submissions:

**closed (20 July 2021)**

### Message from the Guest Editors

Vaccination has made an undeniable contribution in the prevention of numerous infectious diseases and associated morbidity and mortality, and represents a key pillar of an efficient healthcare system. The relationship between vaccination and autoimmune disease has been questioned for decades, after observing a relationship between Guillain Barré syndrome and the swine influenza vaccine in the 1970s.

Cases of vaccination-triggered autoimmune neurological diseases remain rare and poorly understood. On the other hand, autoimmune neurological diseases are often treated with immunosuppressive therapies. Whether vaccines are as effective with each treatment approach needs further clarification. Moreover, recommendation guidelines for vaccination schedules in such patients have been developed for some disorders but remain elusive.

The role of this Special Issue is to provide an updated review of current knowledge in the field of vaccination and neurological autoimmune disorders in an attempt to guide practice. We cordially invite you to participate in this Special Issue, based on your extensive knowledge and experience in the field.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)